- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01862523
Mechanisms of Capsaicin Treatment in Idiopathic Rhinitis Patients and Controls
December 4, 2014 updated by: Universitaire Ziekenhuizen KU Leuven
Unraveling the Mechanisms of Capsaicin Treatment in Idiopathic Rhinitis Patients and Controls by Measuring Mucosal Potentials in the Nose.
Capsaicin nasal spray is used in daily practice against IR without knowledge about the exact mechanisms involved in this treatment.
Therefore, this study aims to address this issue by studying the functional (electrophysiologic) changes after specific stimulations in IR patients and healthy controls before and after capsaicin/placebo treatment.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
As an essential step towards the improvement of the treatment of IR we will investigate the neural mechanisms underlying the therapeutic action of capsaicin.
In particular, we plan to evaluate the effects of capsaicin on the functional properties of the innervation of nasal mucosa by monitoring the trigeminal nerve activity using measurements of negative mucosa potentials (NMP).
NMPs, will be evoked by chemical and thermal stimuli in IR patients and healthy controls.
Considering the evidence suggesting a role of sensory C-fibers in the pathophysiology of IR, we will employ low concentrations of irritants that specifically activate receptors expressed in those fibers, i.e., capsaicin for TRPV1 and cinnamaldehyde and allyl-isothiocyanate (mustard oil) for TRPA1.
The same stimulations will be performed immediately after capsaicin treatment, and after 4 weeks, 3 months and 6 months.
This will allow for an objective assessment of the functionality of the C-fiber innervation before the treatment, during the phase of therapeutic response and during the period of recurrence of the IR symptoms.
The results of the NMP measurements will be contrasted with the therapeutic response and with evaluations of nasal congestion, nasal sensitivity and the presence of neuro-mediators found in nasal biopsies.
Importantly, the independent assessment of the NMP responses mediated by either TRPV1 or TRPA1 will allow determining the specific role of these nociceptors in the pathophysiology of IR, which, in turn, may help to design more specific and effective therapies.
Study Type
Interventional
Enrollment (Actual)
39
Phase
- Phase 4
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Vlaams-Brabant
-
Leuven, Vlaams-Brabant, Belgium, 8000
- UZ Leuven
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 60 years (ADULT)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Patients with persistent (> 52w) rhinological symptoms: nasal discharge, sneezing, congestion for an average of at least 1 h per day for at least 5 days during a period of 14 days, negative skin prick test or negative RAST, and without structural abnormalities explaining nasal obstruction will be proposed to participate in the trial.
- Age > 18 and < 60 years
- Written informed consent
- Willingness to adhere to visit schedules
- Adequate contraceptive precautions in female patients with childbearing potential
- Unresponsiveness to nasal steroid spray (4 weeks of use)
Exclusion Criteria:
- Age < 18 and > 60 years
- Patients with AR, demonstrated by either positive skin prick test or RAST
- Asthma
- Structural abnormalities: nasal polyps, severe septal deviation (septum reaching concha inferior or lateral nasal wall.
- Systemic steroid treatment less than 4 weeks before the inclusion in the study.
- Nasal steroid spray less than 4 weeks before the inclusion, oral leukotriene antagonists or long-acting antihistamines less than 2 weeks before the inclusion.
- Inability of the patient to stop taking medication affecting nasal function.
- Evidence of infectious rhinitis/rhinosinusitis.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NON_RANDOMIZED
- Interventional Model: PARALLEL
- Masking: TRIPLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
PLACEBO_COMPARATOR: diluent
|
diluent
|
EXPERIMENTAL: capsaicin
|
Thirty-three* well-characterized IR patients will be recruited and screened for participation in this study with nasal capsaicin spray (0,1 mmol/l ) using the treatment regimen described by van Rijswijk et al. (1 x 5 applications in one day, with 1 hour between each application)
|
NO_INTERVENTION: control healthy volunteers
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
negative mucosa potentials
Time Frame: baseline, 1, 3 and 6 months
|
change in negative mucosa potentials (baseline vs 1, 3 and 6 months after treatment)by measurement of AUC, delay-time and amplitude
|
baseline, 1, 3 and 6 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
visual analogue scale
Time Frame: baseline, 1, 3 and 6 months
|
change of visual analogue scale of the administered stimuli (baseline vs 1, 3 and 6 months after treatment)
|
baseline, 1, 3 and 6 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Laura Van Gerven, Doctor, UZ Leuven
- Principal Investigator: Peter Hellings, Doctor, UZ Leuven
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
February 1, 2012
Primary Completion (ACTUAL)
December 1, 2014
Study Completion (ACTUAL)
December 1, 2014
Study Registration Dates
First Submitted
September 5, 2012
First Submitted That Met QC Criteria
May 21, 2013
First Posted (ESTIMATE)
May 24, 2013
Study Record Updates
Last Update Posted (ESTIMATE)
December 5, 2014
Last Update Submitted That Met QC Criteria
December 4, 2014
Last Verified
December 1, 2014
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- mucosal potentials in the nose
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Rhinitis
-
Universitaire Ziekenhuizen KU LeuvenAZ Sint-Jan AVRecruitingPerennial Allergic Rhinitis | Seasonal Allergic Rhinitis | Local Allergic RhinitisBelgium
-
Organon and CoCompletedPerennial Allergic Rhinitis | Seasonal Allergic Rhinitis
-
ALK-Abelló A/SCompletedPerennial Allergic Rhinitis | Seasonal Allergic Rhinitis
-
BayerCompletedSeasonal Allergic Rhinitis | Vasomotor Rhinitis
-
Humanis Saglık Anonim SirketiCompletedPerennial Allergic Rhinitis | Seasonal Allergic RhinitisIndia
-
Organon and CoCompletedPerennial Allergic Rhinitis | Seasonal Allergic Rhinitis
-
Organon and CoCompletedPerennial Allergic Rhinitis | Seasonal Allergic Rhinitis
-
SanofiCompleted
-
SanofiCompleted
Clinical Trials on diluent
-
Sorrento Therapeutics, Inc.WithdrawnOsteoarthritis, Knee | Knee Pain Chronic
-
Regeneron PharmaceuticalsNot yet recruitingAmyotrophic Lateral Sclerosis (ALS) | Mutation in the Superoxide Dismutase-1 (SOD1) Gene
-
Pacira Pharmaceuticals, IncCompletedOsteoarthritis, KneeUnited Kingdom, Spain, Canada, Austria
-
OliPass CorporationNovotech (Australia) Pty LimitedRecruiting
-
SanofiCompletedJapanese Encephalitis | EncephalitisAustralia
-
University Health Network, TorontoMcMaster UniversityCompletedMajor Depressive DisorderCanada
-
GlaxoSmithKlineCompletedCardiovascular DiseaseJapan
-
SanofiCompleted
-
International AIDS Vaccine InitiativeBrigham and Women's Hospital; George Washington University; Redemption Hospital; East-West Medical Research InstituteActive, not recruitingLassa Fever | Lassa Virus InfectionUnited States, Liberia
-
Bandim Health ProjectRadboud University Medical CenterCompletedInnate Immunity | Bacille Calmette-GuérinGuinea-Bissau